NBIX:NASDAQ
Neurocrine Biosciences, Inc
$141.37
0.00%
(0.00) 1D
$137.52
arrow_downward
-2.72% (-3.85)todayPre-market
Closed: Oct 12, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NBIX...
Mkt. cap
14.37B
Avg. vol.
1.30M
Volume
9.91K
P/E ratio
20.72
52-wk high
$186.12
52-wk low
$122.14
EPS
$6.82
Beta
0.40
Shares outstanding
101.65M
No. of employees
2K
Mkt. cap
14.37B
Avg. vol.
1.30M
Volume
9.91K
P/E ratio
20.72
52-wk high
$186.12
52-wk low
$122.14
EPS
$6.82
Beta
0.40
Shares outstanding
101.65M
No. of employees
2K
News stories
From web sources and news partners
Stock Traders Daily
·
6 hours ago
Discipline and Rules-Based Execution in NBIX Response
Stock Titan
·
17 hours ago
Neurocrine is set to release Q3 results at 1 p.m. Pacific on Nov. 2, then host a call.
Porterville Recorder
·
17 hours ago
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
Profile
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
About Neurocrine Biosciences, Inc
CEOKevin C. Gorman
Employees2.5K
Founded1992
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websiteneurocrine.com